Tocotrienol Nanoparticle Formulations for Targeted Cancer Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery methods for Vitamin E compounds, such as tocotrienol, fail to effectively target and deliver a therapeutic amount to specific areas in mammals, particularly for cancer treatment, due to inefficiencies in existing delivery methods.
Innovation Solution
Development of pharmacological compositions comprising nanoparticles with a mean diameter of less than 1000 nm, containing a therapeutic amount of tocotrienol, a non-tocotrienol lipid, and a surface active agent, which are designed to enhance targeted delivery through specific formulations and delivery methods like intravenous, intraperitoneal, subcutaneous, ocular, oral, transdermal, and inhalation routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional drug delivery methods are used for Vitamin E compounds, then the delivery system is simple, but the therapeutic amount cannot be effectively delivered to targeted areas
Solution Approach 1:
The delivery system is segmented into nanoparticles with specific size ranges (mean diameter less than 1000 nm, preferably less than 400 nm or 250 nm). This segmentation enables targeted delivery to specific areas while maintaining therapeutic efficacy, resolving the contradiction between delivering sufficient therapeutic amount and keeping the system manageable.
Solution Approach 2:
The patent uses composite nanoparticle formulations containing tocotrienol, non-tocotrienol lipids, and surface active agents. This composite approach allows the delivery system to achieve both targeted delivery capability and therapeutic effectiveness simultaneously, overcoming the limitation of conventional simple delivery methods.
2Manufacturing precision
If nanoparticle formulations with small mean diameter are used, then targeted delivery is enhanced, but manufacturing precision requirements increase
Solution Approach 1:
The patent specifies precise parameter ranges for nanoparticle formulation, including mean diameter (less than 1000 nm, preferably less than 400 nm or 250 nm), polydispersity index (below 0.3), and specific weight ratios of components. These controlled parameters ensure both manufacturing feasibility and reliable targeted delivery effectiveness.
Solution Approach 2:
The patent applies local quality control by specifying different requirements for different aspects of the nanoparticle system: size distribution (polydispersity below 0.3) for uniformity, specific diameter ranges for targeted delivery, and component ratios for stability. This localized quality approach balances manufacturing precision with delivery reliability.
3Quantity of substance
If high concentration of tocotrienol is delivered, then therapeutic efficacy is improved, but stability of the composition decreases
Solution Approach 1:
The patent formulates tocotrienol with non-tocotrienol lipids and surface active agents in specific ratios (sum of tocotrienol and non-tocotrienol lipid weight equivalent to or greater than the weight of surface active agent). This composite formulation maintains high tocotrienol concentration for therapeutic efficacy while ensuring composition stability through the stabilizing effects of the other components.
Solution Approach 2:
The patent controls the physical and chemical parameters of the formulation, including maintaining specific weight ratios of components and controlling particle size, to achieve a balance between high tocotrienol concentration and composition stability. The specified parameter ranges ensure both therapeutic efficacy and stability over time.
4Adaptability or versatility
If multiple delivery routes are available, then versatility is improved, but selection and optimization complexity increases
Solution Approach 1:
The nanoparticle formulation is designed with universal characteristics that enable it to be administered through multiple routes (intravenous, intraperitoneal, subcutaneous, ocular, oral, transdermal, and inhalation). The standardized nanoparticle structure with controlled size and composition provides multi-functionality, allowing the same formulation to work across different delivery routes without requiring separate optimization for each route.
Data Source
AI summary
Compositions containing tocotrienol, non-tocotrienol lipids and surface active agents; compositions containing particles having a statin and a tocotrienol wherein the particle size is less than 1000 nm; and microemulsions containing a statin and a tocotrienol are disclosed. Methods relating to the creation of such compositions and the use of such compositions are further disclosed.